FGL2 and brain neoplasm: have demonstrated that FGL2 inhibits the differentiation of CD103+ dendritic cells (DCs) induced by granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) by suppressing NF‐κB, STAT1/5 and p38 activation, consequently promoting the progression of brain tumours.22